MetaCap

Milestone Pharmaceuticals (MIST) vs Verrica Pharmaceuticals (VRCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Verrica Pharmaceuticals (VRCA) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 34.9% versus a loss of 84.5%. Over five years, MIST leads with a -93.8% price change compared with -97.4% for VRCA. Verrica Pharmaceuticals is the larger company by market cap ($47.1 million vs $46.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIST-84.54%VRCA-34.92%
+126%+16%-95%
Nov 21, 20251 yearNov 20, 2026
MIST-93.88%VRCA-97.60%
+64%-20%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIST versus VRCA key metrics
MetricMISTVRCA
Share price$0.3711$2.74
Market cap$46.20M$47.07M
1-day change-7.06%-5.03%
YTD return-81.63%-67.03%
1-year return-84.54%-34.92%
5-year return-93.85%-97.38%
EPS (TTM)$-0.74$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$35.58M
Revenue growth (YoY)—+370.22%
Net income (latest FY)$-63.06M$-17.89M
Operating margin—-34.25%
Net margin—-50.27%
52-week high$3.06$9.82
52-week low$0.362$2.73
Distance from 52-week high-87.87%-72.10%
Analyst consensusnonestrong_buy
Avg. price target upside+1479.09%+404.74%
Average volume1.53M68.78K
Shares outstanding124.50M17.18M
Employees3876
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VRCA has outperformed MIST by 49.6 percentage points over the past year.

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Verrica Pharmaceuticals

VRCA stock →

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

MIST vs VRCA FAQ

Which is bigger, Milestone Pharmaceuticals or Verrica Pharmaceuticals?

Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $47.07M compared with $46.20M for Milestone Pharmaceuticals (MIST).

Which stock has performed better over the past year, MIST or VRCA?

VRCA returned -34.92% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.

Are Milestone Pharmaceuticals and Verrica Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons